

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1066)

VOLUNTARY ANNOUNCEMENT OPERATIONAL UPDATE FOR THE THIRD QUARTER

This announcement is published on a voluntary basis by the board of directors (the “**Board**”) of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”, together with its subsidiaries known as the “**Group**”) to provide an operational update on the business of the Group.

For the three months ended 30 September 2025, the Company recorded an unaudited revenue of approximately RMB3.26 billion, representing a year-on-year increase of approximately 2.6%. Among which, orthopaedic, interventional and blood management segments achieved relatively faster revenue growth while pharma packaging and medical device segments continued to operate under pressure due to sales prices pressures of products such as flushing syringes affected by government policy, thereby slowing down the overall sales revenue growth of the Group.

* For identification purpose only

The following sets out the year-on-year changes in revenue for each operating segment:

Operating segment	Year-on-year changes
Medical device	Low single-digit decrease
Pharma packaging	Low single-digit increase
Orthopedic	Approximately 10% increase
Interventional	Over 10% increase
Blood management	Over 10% increase

Shareholders and potential investors of the Company should note that this announcement has been prepared based on the Group's unaudited operating information, which has not been audited or reviewed by the Company's auditors. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

3 November 2025
Weihai, Shandong, the PRC

As at the date of this announcement, the Board comprises:

Mr. Long Jing (*Executive Director*)
Mr. Cong Rinan (*Executive Director*)
Mr. Lu Junqiang (*Executive Director*)
Mr. Wang Daoming (*Executive Director*)
Mr. Chen Lin (*Non-executive Director*)
Mr. Tang Zhengpeng (*Non-executive Director*)
Mr. Li Guohui (*Independent Non-executive Director*)
Mrs. Meng Hong (*Independent Non-executive Director*)
Mr. Li Qiang (*Independent Non-executive Director*)
Mr. Sun Heng (*Independent Non-executive Director*)

* *For identification purposes only*